<DOC>
	<DOC>NCT01076075</DOC>
	<brief_summary>This study will evaluate whether the addition of Sitagliptin treatment provides a greater decrease in A1C levels compared to placebo in participants with inadequate glycemic control on sulfonylurea and metformin combination therapy.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Type 2 diabetes mellitus Hemoglobin A1C of ≥7.5% and ≤10.5% Currently taking a stable dose of metformin (at least 1500 mg/day) and either glimepiride (at least 2 mg/day) or gliclazide (at least 50% of maximum registered dose) for at least 10 weeks prior to study start Male, or a female who is highly unlikely to conceive Type 1 diabetes mellitus or ketoacidosis Taking a dipeptidyl peptidase4 (DPP4) inhibitor (such as sitagliptin) or a glucagonlike peptide1 (GLP1) mimetic (such as exenatide or liraglutide) or required insulin therapy within 12 weeks prior to study start On a weight loss program not in the maintenance phase or on a weight loss medication History of liver disease, heart failure, heart disease, stroke, high blood pressure, blood disorders, or cancer HIV positive Pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>